1. Introduction
Isoprenoids represent a diverse family of natural products. They are present in all living organisms as essential primary metabolites (e.g., sterols modulating fluidity and permeability of eukaryotic membranes, carotenoids in photosystems of phototrophic organisms, prenyl chains of quinones involved in electron transport systems, or polyprenol derivatives serving as carbohydrate transporters) and as specialized metabolites of less obvious biological significance (e.g., mono- and diterpenes from essential oils, triterpenes, and meroterpenoids where a terpenoid is linked to a non-terpenic moiety).
Despite their diversity, isoprenoids are synthesized in all living organisms through the assembling of the same two universal C5 building blocks, namely isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) (Scheme 1). Their biosynthesis occurs in different taxons via two distinct and independent pathways. The mevalonate pathway discovered in the 1950s and starting from acetyl coenzyme A is the sole source of the isoprene units in animals, fungi, and the cytoplasm of all phototrophic eukaryotes, in a few bacteria, and in Archaea. In contrast, an alternative mevalonate-independent route, the 2-C-methyl-ᴅ-erythritol pathway (Scheme 1), discovered in the mid-1990s, is present in all phototrophic organisms (plants and algae) and phylogenetically related taxa (e.g., Plasmodium spp.), though its presence in plants is restricted to the plastids, as well as in nearly all bacteria, including many pathogens [1,2,3]. Starting from pyruvate and ᴅ-glyceraldehyde 3-phosphate (ᴅ-G3P), the first step of the pathway catalyzed by the 1-deoxy-ᴅ-xylulose 5-phosphate synthase (DXS) gives 1-deoxy-ᴅ-xylulose 5-phosphate (DXP) [4], a branching point metabolite also required for the biosynthesis of essential cofactors such as pyridoxal phosphate (PLP) (vitamin B6) [5,6] and thiamine diphosphate (ThDP) (vitamin B1) [7,8]. The conversion of DXP into 2-C-methyl-ᴅ-erythritol 4-phosphate (MEP), the key intermediate of this pathway, is catalyzed by the 1-deoxy-ᴅ-xylulose 5-phosphate reductoisomerase (DXR/IspC). The next steps consist of MEP modifications and activation catalyzed by the 2-C-methyl-ᴅ-erythritol 4-phosphate cytidyl transferase (IspD), the 4-(cytidine 5′-diphospho)-2-C-methyl-ᴅ-erythritol kinase (IspE) and the 2-C-methyl-ᴅ-erythritol 2,4-cyclodiphosphate synthase (IspF), followed by two reduction steps catalyzed by the 2-C-methyl-ᴅ-erythritol 2,4-cyclodiphosphate reductase (IspG) and the 4-hydroxy-3-methylbut-2-enyl diphosphate reductase (IspH), respectively [4].
The absence of the MEP pathway in humans and its presence in many human pathogens such as Pseudomonas, Klebsiella, and Mycoplasma, as well as Toxoplasma and Plasmodium species, make all its enzymes attractive targets for designing original antimicrobials and therefore have spurred intense research worldwide [9].
In 2001, the last intermediate of the MEP pathway, the (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP), was identified to activate Vγ9Vδ2 T cells, which play a crucial role in the immune system [10]. Thus, it is interesting to note that the MEP pathway is essential for the viability of human pathogens and concurrently triggers an immune response inducing their death.
Moreover, the 5-hydroxypentane-2,3-dione (laurencione, Scheme 1), a bacterial metabolite produced by Escherichia coli DXS [11], the first enzyme of the MEP pathway, from free ᴅ-glyceraldehyde and from pyruvate, exhibits a close structural resemblance to a small signal molecule, (S)-4,5-dihydroxy-2,3-pentanedione (DPD). This suggests an unsuspected role of the MEP pathway in the mechanisms of bacterial cell communication [12].
The present work gives a brief overview of the multifaceted roles of the MEP pathway as (i) a highly selective antibacterial target, (ii) the most potent known phosphoantigen source, and (iii) a potential contributor to quorum sensing (QS) mechanisms.
Finally, we discuss the new perspectives opened by the MEP pathway functional duality as well as new cryptic functions related to the QS.
2. Antibacterials
Today, antimicrobial resistance (AR) and healthcare-associated infections (HCAIs) can be referred to as a silent pandemic and are among the world’s most pressing public health problems, leading to increase patient morbidity and mortality, thus becoming a significant economic concern. Numerous microorganisms associated with these HCAIs and ARs include mainly Gram-negative bacteria (e.g., Neisseria gonorrhoeae, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecium, and Acinetobacter spp.) but also some Gram-positive bacteria (e.g., Staphylococcus aureus). To treat bacterial infections, the majority of currently used antibiotics target the biosynthesis of proteins, nucleic acids, and cell wall constituents. In addition, the antibiotics introduced to the market in recent decades are analogs of molecules discovered in the eighties [13]. Consequently, bacteria have developed multiple resistance mechanisms leading to a drastic loss of efficiency of the current antibacterial treatments.
Therefore, there is an urgent need to find innovative therapeutic targets essential for bacterial survival for the development of new antibacterial strategies. Absent in humans, the MEP pathway is a very attractive target owing to the druggability of all its enzymes, a potential for a new class of antibiotics with expected minor side effects for humans.
2.1. Inhibitors of DXS
DXS is a dimeric thiamine diphosphate (ThDP)-dependent enzyme [14]. It catalyzes the first and rate-limiting step of the MEP pathway, which consists of a decarboxylative condensation of two products of glycolysis: ᴅ-G3P and pyruvate into 1-deoxy-ᴅ-xylulose 5-phosphate (DXP). The diverse roles of DXP as a precursor not only to isoprenoid precursors IPP and DMAPP but also to ThDP and PLP make DXS an attractive antibacterial target [15,16]. Nonetheless, only a small number of DXS inhibitors have been reported so far, probably due to the lack of available structural information on this enzyme.
The first reported DXS inhibitors were a commercial herbicide ketoclomazone 1 and its hydrolyzed derivative 2. (Figure 1) [17,18]. Both inhibit the DXS of Haemophilus influenzae and E. coli at mid to low micromolar concentration in an uncompetitive manner with respect to pyruvate and exhibit a moderate effect on the bacterial growth of these pathogens.
A series of aromatic oxime DXS inhibitors was developed, among which 2,4,5-trihydroxybenzaldoximes 3 (Figure 1) have been identified to exhibit Ki values within the one-digit micromolar range [19]. These inhibitors are competitive against ᴅ-G3P and uncompetitive against pyruvate. However, the development of antibacterial drugs based on these compounds may be problematic as the trihydroxyphenyl moieties are readily oxidized in vivo, forming highly electrophilic and thus toxic quinones. Meyers et al. prepared a series of alkylacylphosphonates 4 (Figure 1), unnatural bisubstrate analogs including a pyruvate mimic and a nonpolar acceptor allowing the formation of irreversible complexes with ThDP in the active site of the enzyme [20,21]. These bisubstrates are selective DXS inhibitors of several pathogens (M. tuberculosis, Salmonella enterica, and Yersinia pestis) in the low micromolar range. Recently, a library of triazole-based alkylacylphosphonates has been reported, among which compound 5 (Figure 1) emerged as the most potent inhibitor against E. coli DXS (Ki = 90 nM) with a great selectivity (more than 15,000-fold) over porcine pyruvate dehydrogenase. However, due to the poor permeability of the bacterial plasma membrane towards these potential drugs, they exhibit weak antibacterial activity against Gram-negative (e.g., E. coli, S. enterica) and Gram-positive bacteria (e.g., Bacillus anthracis) [22]. To improve their uptake into the cells, peptidic enamide prodrugs of alkylacylphosphonates have been recently prepared, allowing an increase in their antibacterial activity against Gram-negative pathogens and decreasing their minimum inhibitory concentrations by nearly 2000-fold in comparison with free inhibitors (e.g., 6, Figure 1) [23]. Finally, a series of 3-diazathiamine diphosphate analogs (e.g., 7, Figure 1) widely studied as inhibitors of a large collection of ThDP-dependent enzymes has been reported to inhibit M. tuberculosis DXS with a sub-micromolar activity [24].
2.2. Inhibitors of DXR/IspC
DXR, the second enzyme of the MEP pathway, catalyzes a two-step reaction: the Mg2+-triggered rearrangement of DXP into a non-isolable aldehyde and its concomitant NADPH-dependent reduction into MEP. DXR is a particularly well-described enzyme of the MEP pathway, with numerous protein crystal structures from several organisms, including important pathogens (e.g., E. coli, M. tuberculosis, Y. pestis). Additionally, its active site was assessed as a particularly druggable pocket [9]. However, the design of DXR inhibitors is challenging due to strong conformational changes of the enzyme upon ligand binding [9] and a great dependence of the inhibitor efficiency on the bacterial species.
In 1980, fosmidomycin 8 and its acetylated analog FR-900098 9 (Figure 2), two phosphonoretrohydroxamic acids originally isolated from Streptomyces spp. culture broths were shown to exhibit antibacterial activity against a wide variety of bacteria, mainly Gram-negative ones. Twenty years later, the discovery of the MEP pathway has highlighted data on the mechanism and the target of those phosphonic acid antibiotics. Fosmidomycin was shown to inhibit the DXR of E. coli in a mixed (competitive with respect to DXP and uncompetitive relative to NADPH), low tight-binding manner, with a Ki value of 38 nM [25,26,27].
This natural antibiotic binds to the DXR active site via hydrogen bonds between the phosphonate moiety and polar amino acid residue and chelates the divalent cation through its retrohydroxamate metal-binding group.
Although fosmidomycin 8 and its analog 9 efficiently inhibit the DXR enzyme of a wide range of bacteria, they have several limitations to being used as suitable antibacterial agents: (i) fosmidomycin-resistant strains have already appeared [28]; (ii) fosmidomycin is ineffective against some pathogens [29]; (iii) fosmidomycin exhibits fast clearance by the kidneys and a low biodisponibility to bacterial cells due to its highly polar hydrophilic nature [30]. The presence of the negative charge on the phosphonate group prevents fosmidomycin from entering the bacterial cell by passive diffusion, and consequently, the drug has to be actively transported across the membranes to reach its target, e.g., through a transporter in the E. coli cytoplasmic membrane (G3P transporter GlpT) or through specific porins in the P. aeruginosa outer membrane [31]. Fosmidomycin is therefore inefficient against pathogens such as M. tuberculosis lacking such an active transport.
Fosfoxacin 10a, a phosphate analog of fosmidomycin isolated from the filtrate of a Pseudomonas fluorescens culture, [32] and its acetylated analog 10b (Figure 2) inhibit DXR of a cyanobacterium Synechocystis sp. with Ki values of 19 and 2 nM, respectively, vs. 58 nM for fosmidomycin [33]. Fosfoxacin also inhibits the growth of different bacterial strains; in particular, good activity was observed against Micrococcus luteus with a minimum inhibitory concentration (MIC) value of 0.2 μg mL−1 [32]. The in vitro activity of fosfoxacin on the DXR of E. coli was, however, rather modest, with an IC50 value about 8 times higher than that of fosmidomycin and 85 times higher than that of FR-9000098. Nevertheless, its acetylated analog 10b inhibits E. coli and Mycobacterium smegmatis enzymes with an efficiency similar to that of fosmidomycin [34].
Due to the emergence of numerous clinical multidrug-resistant strains, research efforts were dedicated to the development of more effective DXR inhibitors. To improve the activity of the natural phosphonic acids, several groups performed various structure modifications that can be classified into three main categories (Figure 2): (i) replacement of the retro-hydroxamate chelating group with a different metal-binding group; (ii) replacement of the phosphonate anchoring group by phosphonate bioisosters; (iii) modification of the carbon spacer (length change, introduction of an aromatic substituent, introduction of fluorine atoms, replacement of a carbon atom with a heteroatom).
These detailed structure-activity relationship studies showed that neither the retrohydroxamate nor hydroxamate chelating moiety nor the phosphate/phosphonate anchoring group can be replaced, and the length of the spacer (3 atoms) cannot be changed without a drastic loss of DXR inhibitory activity [33,35,36,37].
The synthetic analog of fosmidomycin 12, in which the retrohydroxamate moiety is inversed into hydroxamate (Figure 2) [26], inhibited DXR of E. coli nearly as efficiently as fosmidomycin with a Ki value of 54 nM and inhibited M. smegmatis DXR almost as efficiently as FR-900098. In addition, it suppressed the growth of this bacterium at 50 µM and the growth of an E. coli fosmidomycin-resistant strain at 200 µM [26,38]. Its phosphate analog 13 (Figure 2) had a very similar IC50 value for the E. coli enzyme and an even lower value for the M. smegmatis DXR. It also presented an antibacterial activity similar to those of fosfoxacine 10a and its acetylated homolog 10b against E. coli [39].
To mimic the phosphate group and increase the bioavailability, the substitution of the α,α-methylene group in phosphonate DXR inhibitors with electron-withdrawing substituents, in particular fluorine atoms, has been considered. The α,α-difluoromethylene, an isopolar mimic of the oxygen component of the P–O–C linkage in phosphates, favors the DXR inhibition and enhances the antimicrobial activity compared to the phosphates and non-fluorinated phosphonates. For example, the N-methylated α,α-difluorophosphonates 11 and 14 (Figure 2) exhibited stronger inhibition activity than that of the reference compound fosmidomycin against E. coli DXR with IC50 values of 9 nM and 17 nM, respectively. Moreover, a direct relationship between the capacity to inhibit the DXR and the bacterial growth was observed for α,α-difluorinated inhibitors [40].
The influence of aromatic substituents in the α-position respective to the fosmidomycin phosphonate group has also been investigated. A series of analogs was prepared, and their activity was evaluated on E. coli DXR [9,41]. The 3,4-dichlorophenyl fosmidomycin analog 15 (Figure 2) emerged as the most potent analog of this series with a submicromolar inhibitory activity against E. coli DXR (IC50 = 59 nM) [42]. The substitution of the methylene group in the β-position relative to the phosphonate group of 12 with a sulfur atom resulted in a dramatic improvement of the inhibitory efficiency. Indeed, compound 16 (Figure 2) exhibited IC50 values almost two orders of magnitude lower than fosmidomycin with respect to the enzymes of E. coli and M. tuberculosis [43]. This compound also inhibited the DXR of Y. pestis with a potency about three times higher than that of fosmidomycin, and it suppressed the growth of this pathogen with a similar efficiency [44].
Unlike conventional DXR inhibitors, compound 17 (Figure 2), containing an O-linked naphthyl moiety, which cannot efficiently chelate the metal cation in the active site of the enzyme, displayed a more potent inhibition against Y. pestis DXR (IC50 = 0.35 µM) than against its M. tuberculosis homolog (IC50 = 1.45 µM). This type of compound may occupy both DXP and NADPH binding sites and acts as a competitive bisubstrate inhibitor of DXR with respect to both DXP and NADPH. However, 17 does not appreciably suppress the E. coli and Y. pestis growth, partially because of an active efflux [45].
An important challenge in antibacterial drug development is the discovery of new antitubercular medicines, as the current treatment of tuberculosis is lengthy, associated with unpleasant side effects, and often ineffective due to the emergence of resistant M. tuberculosis strains [27]. To solve this problem, targeting the enzymes of the MEP pathway, especially DXR, is often attempted.
However, fosmidomycin, FR-900098, and many of their analogs [27] do not suppress the growth of Mycobacterium spp. despite their activity towards mycobacterial DXR. This is caused by the lack of uptake as Mycobacterium spp. are characterized by an extremely thick and hydrophobic cell wall rich in mycolic acids [37] and glpT homolog gene in the M. tuberculosis genome [46,47].
To overcome the absence of mycobacterial cell wall crossing by the natural DXR inhibitors 8 and 9 as well as by the synthetic N-methylated phosphonohydroxamate 12, the prodrug strategy was adopted. Several prodrugs of fosmidomycin and its analogs were synthesized by masking the negative charge of the phosphonate group present at physiological pH with hydrophobic groups such as acyloxymethyl and alkoxycarbonyloxymethyl moieties. Among such lipophilic esters of FR-900098, compound 18 (Figure 3) has been shown to be the most potent anti-M. tuberculosis activity, inhibiting the growth of M. tuberculosis with a MIC between 25 and 100 μg mL−1 [48]. A similar result was observed with its acyloxymethyl phosphonate ester prodrug analog 19 (Figure 3), with a MIC value against M. smegmatis between 250 and 500 μM. The parent molecules are liberated inside the bacterial cells by non-specific esterases [38].
Recently, another successfully tested approach on M. tuberculosis was the use of phosphonodiamidate prodrugs derived from amino acid esters. Among the series, the ethyl
To increase the lipophilicity of O-linked aromatic inhibitors such as 17 (Figure 2), their bis-pivaloyloxymethyl (POM) ester prodrugs were prepared and have shown improved efficiency against M. tuberculosis, but no activity against E. coli and Y. pestis was observed due to their active efflux. Compound 23 (Figure 3) efficiently inhibited the growth of M. tuberculosis with a MIC value varying according to the media used: 12.5 µg mL−1 (7H9 media) or between 3.13 and 6.25 µg mL−1 (GAST-Fe media) [45].
In search for new antitubercular compounds, a series of eleven double prodrugs of the phosphonohydroxamate 12 (Figure 2), in which the phosphonate group is masked with a POM moiety and the hydroxamate with various functional groups (ether, ester, carbamate, and bioreducible nitro aromatic group), were prepared. Only double prodrugs 24 and 25 (Figure 3) displayed promising antitubercular activity with a MIC value of 12.5 µM [50].
2.3. Inhibitors of IspD/YgbP
The third enzyme of the MEP pathway is a cytidyl transferase catalyzing the transfer of the cytidyl phosphate group from cytidine triphosphate (CTP) to the phosphorus atom of MEP, leading to 4-diphosphocytidyl-2-C-methyl-ᴅ-erythritol (CDP-ME) and inorganic diphosphate [51,52].
The design of substrate-competitive IspD inhibitors is challenging, as its active site is rather solvent-exposed and the least lipophilic of all the enzymes of the MEP pathway [9,53]. Moreover, the presence of a homologous cytidyl transferase in human cells, hISPD, may prevent the application of discovered inhibitors in therapy [54]. Most of the literature on the inhibition of IspD concerns herbicides and antimalarials [9]
Domiphen bromide 27 (Figure 4), an antiseptic quaternary ammonium salt [55], inhibited the IspD of M. tuberculosis with an IC50 value of 33 μg mL−1 and suppressed the growth of M. smegmatis and M. tuberculosis with a MIC of 0.31 μg mL−1 and 8 μg mL−1 respectively, without appreciable loss of activity against clinical drug-resistant isolates of the latter species. It is a competitive IspD inhibitor with respect to CTP and uncompetitive with respect to MEP [56].
Antibacterials targeting the MEP pathway could also function as alternative substrates of its enzymes. Such small molecules would be transformed into nonfunctional analogs of isoprenoid precursors, hence suppressing the isoprenoid production in the bacterial cell. Inhibitors 28 and 29 are such compounds [57].
The demethylated analog of MEP 28 (Figure 4) is a weak competitive inhibitor of E. coli IspD with an IC50 value of 1.36 mM, and it reduced the turnover rate of this enzyme compared to the natural substrate [58,59]. The fluoro analog of MEP 29 is a very weak inhibitor of the E. coli IspD with an IC50 value of 0.7 mM, but no activity was found against the enzyme of M. tuberculosis. In addition, E. coli IspD catalytic efficiency is 250 times lower with 29 than that of the natural substrate [57].
MEPN3 30, an azido analog of MEP (Figure 4), is a mixed-type inhibitor of IspD with respect to both of its substrates, and it may occupy different pockets in the active site. It is characterized by two-digit micromolar Ki values against the enzyme of E. coli [60].
It is interesting to note that fosmidomycin 8 (Figure 2), the potent inhibitor of DXR, also weakly inhibits IspD, with an IC50 value of 20.4 mM for the enzyme of E. coli, and that the overexpression of IspD confers fosmidomycin resistance in this bacterium [61].
2.4. Inhibitors of IspE
The product of IspD, 4-diphosphocytidyl-2-methylerythritol, undergoes the ATP-dependent phosphorylation to 4-diphosphocytidyl-MEP (CDP-MEP). This reaction is catalyzed by IspE, a cytoplasmic kinase originally called YchB. IspE is an Mg2+-dependent [62] kinase belonging to the galactose, homoserine, mevalonate, and phosphomevalonate (GHMP) kinases superfamily, which also encompasses enzymes of the mevalonate pathway [4].
Although kinases related to IspE are present in mammalian cells, it was suggested that distinctive features of the IspE active site should allow its selective targeting, even if its low lipophilicity constitutes an additional challenge for the design of its inhibitors [9]. A high degree of conservation of the amino acids in the active site should enable the design of broad-spectrum antibacterials [9,63]. However, drastic differences in activity with respect to IspE from different bacterial species were observed for some inhibitors [64].
With the aim to obtain selective inhibitors of IspE, the possibility to simultaneously occupy the cytosine-binding pocket in the active site and the neighboring hydrophobic pocket was investigated with substituted cytosine mimics. Competitive and mixed micromolar and submicromolar inhibitors of E. coli IspE were obtained. Among this series, the racemic mixture of 31 (Figure 5) was characterized by the lowest Ki value (290 nM) [65].
Compound 32 (Figure 5), presumably bisubstrate inhibitor of IspE targeting both the 4-diphosphocytidyl-2-methylerythritol- and the ATP-binding sites, has a similar efficiency as 31 [66].
Investigation of known inhibitors of the GHMP kinases superfamily led to the discovery of two new hits for the development of the IspE inhibitors, compounds 33 and 34 (Figure 5). They were characterized by one- or low two-digit micromolar activities against the enzymes of E. coli and Y. pestis [9,67]. Moreover, 33 suppressed the E. coli growth with an activity similar to that of antiseptic hexachlorophene during the first 6 h of the culture, although its effect was drastically reduced later on [67]. In the same study, ten weak E. coli IspE inhibitors were identified by high-throughput in silico screening. The most active of them was compound 35 (Figure 5), which inhibited the enzyme activity by 80% at 20 μM. However, compound 36 (Figure 5), with only a 60% inhibition at the same concentration range, was judged more interesting for further optimization because of the originality of its structure [67].
2.5. Inhibitors of IspF
The formation of 2-C-methyl-ᴅ-erythritol-2,4 cyclodiphosphate (MEcPP) is catalyzed by IspF, the fifth enzyme of the MEP pathway. The activity of this trimeric enzyme depends on two metal cations: Zn2+ and Mg2+ or Mn2+ [4]. The Zn2+ ion coordinates the phosphate group bound to the C4 atom of the substrate [68], increasing its electrophilicity and facilitating its nucleophilic attack at the C2 atom. The resulting intermediate undergoes cyclization, yielding MEcPP and cytidine monophosphate (CMP) [4].
IspF might play an important role in the regulation of the MEP pathway as it may be inhibited by downstream isoprenoid precursors. Structural analysis elucidated the presence of a hydrophobic cavity at the core of the trimer where IPP, DMAPP, geranyl diphosphate (GPP), and farnesyl diphosphate (FPP) were found to bind. However, none of them inhibits IspF. Nevertheless, Bitok and Meyers observed that MEP and 2-C-methyl-ᴅ-erythritol (ME) enhanced IspF activity and stability. Afterward, only FPP turned out to inhibit this IspF-MEP complex, probably binding the hydrophobic cavity. This suggests that MEP binding induces a conformational change in IspF. Thus, feedback regulation of the MEP pathway may occur via the IspF-MEP complex inhibition [69,70].
In addition, the FPP- and GPP-binding hydrophobic cavity of the IspF trimer was assessed as druggable. However, few IspF inhibitors have been described [9]. Therefore, it is interesting to note that interactions of this enzyme with inhibitors may depend on the binding of its allosteric regulators, such as MEP [71].
High-throughput screening led to the identification of thiazolopyrimidines as IspF inhibitors. Among the most potent molecules identified, 37 and 38 (Figure 6) were characterized by IC50 values in the low micromolar range: 2.1 µM and 5.1 µM, respectively, against the IspF of M. tuberculosis and 69 µM and 18 µM, respectively, against the IspF of E. coli [72].
A few two-digit micromolar inhibitors of Burkholderia pseudomallei IspF were identified, among which bis-sulfonamide 39 (Figure 6) is the most potent. The aryl sulfonamide 40, designed by a structure-based rational optimization, presented two-digit micromolar activity against M. tuberculosis IspF [73]. Native electrospray ionization-mass spectrometry and docking experiments suggest that bis-sulfonamides such as 39 inhibit IspF by extracting the zinc cation from the active site and by occupying the substrate-binding pocket. This pocket is capable of binding two bis-sulfonamide molecules or their complex with a Zn2+ ion [74].
In some bacteria, IspD and IspF activities are performed by two domains of a single IspDF protein. Analytical ultracentrifugation experiments suggested that this bifunctional protein from Campylobacter jejuni, as well as IspD and IspF of E. coli, form complexes with the corresponding IspE proteins [4]. However, electrophoresis on native gel and size exclusion chromatography did not confirm the formation of such assemblies for the enzymes of E. coli and B. subtilis [75].
A library of over 100,000 compounds was screened in search of inhibitors of the Helicobacter pylori IspD domain of the bifunctional IspDF enzyme. Three inhibitors characterized by submicromolar activity were found (Figure 6). Compound 41 was shown to reduce the growth of H. pylori to 33% at 19 μM, while 42 and 43 suppressed its growth with MIC of 12.5 μM and 25 μM, respectively. Encouragingly, the latter compound did not reduce the viability of murine fibroblasts in cell culture [76].
Compounds identified as inhibitors of the IspD domain of H. pylori IspDF were also characterized by a weak inhibitory activity against its IspF domain. Compound 44 reduced the production of MEcPP to 57% at 50 μM as determined by a 13C NMR-based assay [76].
2.6. Inhibitors of IspG and IspH/LytB
The last two enzymes of the MEP pathway are [4Fe-4S] cluster-dependent reductases. IspG, originally named GcpE [77], is a dimeric enzyme catalyzing the reductive ring opening of MEcPP into HMBPP, the last intermediate of the MEP pathway. IspH, also called LytB, catalyzes the reduction of HMBPP into IPP and DMAPP in an approximate ratio of 6:1 [4].
A difficulty in the design of IspG inhibitors is the drastic conformational change between its substrate-free and substrate-bound forms. In Thermus thermophilus, a rotation by about 60° in the angle between the two domains of each monomer of the enzyme is observed [4,78].
Despite this drawback, several diphosphate compounds containing alkyne, carboxylate, pyridine, and imidazole moieties were tested as inhibitors of IspG. The propargylic and homopropargylic diphosphates 45 and 46 (Figure 7), characterized by the IC50 values of 750 nM and 770 nM, respectively, with respect to the enzymes of E. coli, were the most potent compounds investigated in this study. The molecules lacking a triple bond were significantly less active, with only three-digit micromolar or millimolar IC50 values [79]. Alkynes probably bind an iron atom in the [4Fe-4S] cluster, forming a ferracyclopropene structure [80]. However, this mode of action gives rise to selectivity issues with respect to mammalian enzymes containing iron-sulfur clusters [9]. Nevertheless, the coordination of the cluster in IspG is very specific, with only three iron atoms coordinated by cysteine sulfur atoms and the fourth one binding a glutamate carboxylate. The latter is then replaced by the hydroxyl group of MEcPP [4,77,81].
Besides the druggable pocket identified in the active site of IspH, which contains an unusually high proportion of apolar amino acid, the presence of allosteric sites that could bind larger substrate analog inhibitors was demonstrated [82]. Most of the IspH inhibitors reported in the literature interact with the [4Fe-4S] cluster. Substrate mimics such as the thiol and amino derivatives of HMBPP 47 and 48 (Figure 7) are excellent inhibitors of E. coli IspH, with reported IC50 values of 210 nM and 150 nM, respectively. The thiol 47 acts as a reversible tight-binding inhibitor, and 48 is a reversible slow tight-binding inhibitor. The inhibitory activity of 48 increases with pH, indicating a more efficient enzyme binding with the non-protonated amino group [83].
Compounds 47 and 48 were also reported to bind the [4Fe-4S] cluster of IspG, exhibiting low micromolar to high nanomolar inhibitory activities against the enzymes of E. coli and P. aeruginosa [84].
Other IspH inhibitors targeting the [4Fe-4S] cluster with notable activities were diphosphates possessing terminal alkyne and nitrile moieties. The most potent compound investigated was 46 (Figure 7), characterized by a 450 nM IC50 value against the IspH of Aquifex aeolicus. In the same study, the effects of the substitution of the triple bond with pyridine moieties were investigated. However, these substitutions caused dramatic decreases in inhibitory activity. Compound 49 (Figure 7) was the most active pyridine-based inhibitor tested, with an IC50 value of 9.1 μM against the IspH of A. aeolicus. Bisphosphate pyridine derivatives were also studied, 50 being the most potent of them with an IC50 of 67 μM (A. aeolicus) [85].
In silico screening led to the identification of a derivative of a barbituric acid 51 (Figure 7) as a non-diphosphate inhibitor of the P. aeruginosa IspH with a Ki value of 500 nM. Its analog 52 is characterized by a Ki of 900 nM and 3 µM against the enzymes of A. aeolicus and E. coli, respectively [86].
Targeting IspH alone can lead to the accumulation of HMBPP, which activates γδ T lymphocytes (cf. part II) and thus may overstimulate the immune response [9]. On the other hand, IspH inhibitors targeting its iron–sulfur cluster were reported to suppress the IspG activity as well [9,82,84], and such double targeting may help prevent the emergence of resistance [82].
3. MEP Pathway as Immunostimulant Source
3.1. Natural Phosphoantigens from the Isoprenoid Biosynthetic Pathways
Phosphoantigens (PAgs) are small non-peptidic phosphorylated molecules capable of activating Vγ9Vδ2 T cells (or Vγ2Vδ2 T cells), a subset of T lymphocytes that express γδ T-cell receptors [87,88]. Displaying innate and adaptative properties, this subset, encountered only in humans, higher primates, and recently found in alpaca cells [89], plays several important roles in the immune system. In particular, it mediates the innate immunity against a wide variety of pathogenic bacteria (e.g., M. tuberculosis) and protozoa (e.g., Plasmodium falciparum) as well as exerts a broad cytotoxicity against human tumor cells [90,91,92]. Thus, Vγ9Vδ2 T cells are promising targets as cell effectors for cancer immunotherapy.
The first natural PAg identified was IPP (Figure 8), reported to induce a Vγ9Vδ2 T-cell response in the micromolar range [93]. Its isomer, DMAPP, was also found to exert PAg activity [94], though a recent study concluded that it rather acts as an indirect PAg through a cellular interconversion into IPP catalyzed by isopentenyl diphosphate isomerase (IDI) [95].
The concentrations of IPP in healthy human cells are not sufficient to trigger Vγ9Vδ2 T-cell activation. However, a dysregulation of the mevalonate pathway observed in several tumor cells leads to the accumulation of endogenous IPP and thus induces a Vγ9Vδ2 T-cell response [96]. Strikingly, aminobisphosphonate drugs (e.g., risedronate and zoledronate), originally developed as a treatment for osteoporosis and metastatic bone disease, were found to activate Vγ9Vδ2 T cells using an indirect mechanism. Indeed, they inhibit the farnesyl diphosphate synthase, an enzyme downstream of IPP, and thus increase the intracellular level of IPP and DMAPP among other prenyl metabolites [91,94,96,97,98].
Surprisingly, simultaneously with the discovery of the role of IPP and DMAPP in Vγ9Vδ2 T-cell activation, it was reported that microbes using the MEP pathway to synthesize IPP, such as M. tuberculosis, E. coli, and P. falciparum, produce phosphoantigens that specifically activate Vγ9Vδ2 T cells [10,99]. A natural ligand of microbial origin for the human Vγ9Vδ2 T-cell receptors was then identified as HMBPP [100,101], which turned out to be about 104 times more potent than IPP in activating human Vγ9Vδ2 T cells at picomolar concentrations (HMBPP EC50 = 0.39 nM vs. IPP EC50 = 10 µM and DMAPP EC50 = 20 µM) [98].
Thus, the last intermediate of the MEP pathway plays a dual role, as it is both required for bacterial growth and triggers the host immune response [102].
3.2. Synthetic HMBPP Analogs
The difference in activity between HMBPP and DMAPP shows the importance of the hydroxyl group at the C4 position for efficient Vγ9Vδ2 T-cell activation. However, the efficiency of natural HMBPP recognition by Vγ9Vδ2 T cells seems limited as (i) HMBPP is produced in very small amounts in bacteria, especially in slow-growing ones (e.g., M. tuberculosis), and (ii) its rapid and strong recognition by Vγ9Vδ2 T cells may seem ineffective for many HMBPP-producing bacteria as they manage to escape the immune response. Therefore, based on the structures of IPP and HMBPP, several PAg agonists for human γδ T lymphocytes have been synthesized (Figure 9) [102,103].
Among these compounds, halohydrin diphosphates mimic the biological properties of natural PAgs and exert an activity similar to HMBPP in inducing Vγ9Vδ2 T-cell proliferation, even though they lack the allylic alcohol moiety. The iodine (IHPP) 53 and bromine (BrHPP) 54 derivatives were the most potent, with EC50 values around 1 nM and 10 nM, respectively (Figure 9) [98,103,104]. When combined with low doses of interleukin-2 (IL-2) as co-treatment, BrHPP even demonstrated strong potential in specific activation of Vγ9Vδ2 T cells in clinical trials for the treatment of hematological malignancies and solid tumors [105,106]. However, no clinical developments of BrHPP have been reported in the literature since then [107]. This can be partly due to the rapid degradation of BrHPP in plasma, with a half-life of only a few minutes. Moreover, a decrease in the Vγ9Vδ2 T-cell proliferation in subsequent BrHPP therapy cycles was observed, and increasingly higher doses of BrHPP might thus be required [106,108]. To improve the stability of HMBPP and BrHPP 54 in vivo, derivatives of HMBPP with modifications of the diphosphate moiety have been synthesized.
Replacing the HMBPP diphosphate group, susceptible to chemical or enzymatic hydrolysis, with a diphosphonate group (CC-HMBPP 55) drastically reduces the capacity of this compound to induce the proliferation of Vγ9Vδ2 T cells. Similarly, a loss of activity is observed when only the second phosphate moiety is substituted by a phosphonate (HMBPCP 56) (Figure 9). In contrast, the replacement of the first bridging oxygen with a carbon atom (C-HMBPP 57) results only in a slight decrease in potency compared to HMBPP (EC50 of 0.91 nM) while increasing the molecule stability. Using a monophosphate or a monophosphonate moiety (C-HMBP 58) also abrogated the PAg activity [98,104,109].
Moreover, the impact of the double bond configuration of the isoprene unit has been studied, and the PAgs in their natural E configuration turned out to be about 600 times more potent than their Z-isomers (E-HMBPP EC50 = 0.39 nM versus Z-HMBPP EC50 = 252 nM) [109].
3.3. Prodrugs of Phosphoantigens
Except for compound 57 (Figure 9), all attempts to increase the stability of the diphosphate group in HMBPP led to a loss of immunostimulatory activity. This is likely due to the acidic properties and the negative charge of the diphosphate or diphosphonate groups at physiological pH, restraining the movement of HMBPP and its synthetic analogs across the membranes and probably limiting the efficiency of HMBPP-based therapies [98]. To overcome these stability and membrane permeability issues, several PAg prodrugs have been synthesized. The bis- and tris-POM prodrugs of the monophosphonate and diphosphonate derivatives of HMBPP, POM2-C-HMBP 59 and POM3-CC-HMBPP 60 (Figure 10), displayed potent activation of Vγ9Vδ2 T-cell proliferation in the low nanomolar range (EC50 = 5.4 nM and 41 nM respectively). The increased potency of 59 and 60 compared to 58 and 57 suggests that the prodrugs release the free phosphonate forms intracellularly [110,111].
Additionally, the monophosphonate delivered by compound 59 is thought to undergo endogenous phosphorylation to give the potent and stable phosphoantigen C-HMBPP 57. These results suggest that the PAg charges act as a barrier for both cellular entry and exit and that the binding of PAgs to the butyrophilin transmembrane protein receptor BTN3A1, responsible for their recognition by Vγ9Vδ2 T cells, occurs intracellularly [110,111].
However, the bis-POM prodrugs still display rather short half-lives in human serum as they are fully metabolized after 2 h. Thus, to further increase the prodrug stability, mixed aryl/POM diester prodrugs 61 with 1- and 2-naphthyl moieties have been synthesized. These two prodrugs exhibited high stability in 50% plasma and pico- and nanomolar potencies in activating the Vγ9Vδ2 T-cell proliferation (61 1-naphthyl EC50 = 0.79 nM; 61 2-naphthyl EC50 = 2.10 nM; HMBPP EC50 = 0.51 nM). The prodrug containing the 1-naphthyl moiety was even about 570-fold more potent than HMBPP in stimulating Vγ9Vδ2 T cells for interferon γ production [112,113].
In parallel, the phosphoramidate prodrug approach was applied to the monophosphate derivative HMBP in order to find a monophosphate prodrug as potent as HMBPP. However, due to the poor stability of the P–O bond in the presence of a deprotected hydroxyl group at the C4 position in these prodrugs, only the protected phosphoramidates 62 could be tested. The most potent compound of the series was the benzyl ester derivative, with an EC50 value of 0.45 nM [114]. The same strategy was tested on the derivatives of the monophosphonate C-HMBP containing (i) different aryloxy groups, (ii) either glycine or
Additionally, the protection of the allylic alcohol in aryloxy diester phosphonamidate prodrugs with a biocleavable protecting group such as the acetate ester (compound 65) increased their potency compared to their free alcohol counterparts and to HMBPP [117].
More recently, modifications at the allylic alcohol of several monophosphonate prodrugs highlighted that the removal of the allylic alcohol abrogates activity; its replacement with an aldoxime simply decreases it, while an aldehyde (compound 66) is well tolerated as it is reduced intracellularly into the corresponding alcohol. Furthermore, using a diene scaffold instead of the classical isoprene unit, even without the hydroxyl group at C4 as in compound 67, turned out to be sufficient to induce stimulation of the Vγ9Vδ2 T cells [95,118].
All the prodrugs mentioned above exhibit mild to no toxicity and specifically activate the proliferation of Vγ9Vδ2 T cells. Thus, the phosphonamidate and mixed aryl prodrug strategies seem to provide interesting candidates as new immunotherapeutics for the treatment of cancer and infectious diseases that can be targeted by Vγ9Vδ2 T cells.
4. MEP Pathway as a Potential Contributor to Bacterial Cell–Cell Communication
4.1. Cell–Cell Communication Signal Molecules in Bacteria
Bacteria are unicellular microbes, but they live communally, inclining us to consider a bacterium more as a component cell of a multicellular organism than a free-living, autonomous biological entity [119]. Thus, bacterial cells have to communicate and cooperate with each other, modifying their behaviors according to changes in their social environment. These interactions are made possible through an extensive repertoire of signaling molecules, also named autoinducers (AIs). These small molecules enable bacterial cells to sense the density of surrounding bacteria and then trigger a coordinated response. Thus, we can consider that bacteria possess a kind of “social intelligence”.
As cell density is a key parameter, these mechanisms are known as quorum-sensing (QS). Interactions between bacteria occur between neighboring cells via soluble molecules or at a distance through volatile apolar organic compounds. These semiochemicals are reported, for example, to inhibit or promote fungal growth [120,121,122]. All these communication mechanisms allow bacteria to detect changes in biotic and abiotic conditions and to respond appropriately to them by switching their phenotypes.
4.2. Inter-Kingdom Communication: (S)-4,5-Dihydroxy-2,3-pentanedione and Its Derivatives
These secreted signal small molecules or autoinducers (AIs) demonstrate high chemical structure variability. Besides the acyl homoserine lactones widely described in the literature [123] and often produced by Gram-negative bacteria, numerous other AIs have been identified. One in particular, (S)-4,5-dihydroxy-2,3-pentanedione 68 (DPD or AI-2), has been known since 1971 [124] and the discovery of its role in QS in Vibrio harveyi by Bassler et al. in 1994 prompted extensive studies of this molecule [125]. DPD is synthesized by the LuxS protein, an enzyme conserved throughout the bacterial kingdom [126]. Hence, LuxS/AI-2 QS system is possibly the first described mechanism of intercellular (intra- and inter-species) communication present in nearly all bacteria. In many of them, it has been linked to pathogenicity [125], and its roles in important physiological functions such as cell signaling, production of virulence factors, stress response, and biofilm formation have been reported [127].
The precursor DPD undergoes various rearrangements to form distinct signal molecular structures, which interconvert in a complex equilibrium. Indeed, in an aqueous solution, DPD, a linear five-carbon molecule, is in equilibrium with cyclic stereoisomeric forms (Scheme 2), all these DPD derivatives being referred to as AI-2. Since different chemical species are recognized by different bacteria, studies of AI-2-mediated QS mechanisms have proved challenging. In V. harveyi, cyclic DPD derivatives coordinate to boron to form S-THMF (tetrahydroxytetrahydrofuran)-borate diester 70, whereas Salmonella typhimurium reacts to R-THMF 69 [128]. Unsurprisingly, studies of synthetic DPD analogs have shown how a small structural modification impacted biological activity. These molecules mediate a variety of QS pathways and regulate numerous genes.
The behavior of P. aeruginosa, which does not produce DPD, has been shown to be impacted by the addition of DPD, which induced the expression of virulence factor genes [129] and regulated the formation of biofilm and bacterial viability in a dose-dependent manner [130]. In E. coli, the DPD analogs, isobutyl-DPD 71 and phenyl-DPD 72 inhibited the maturation of biofilm [131]. In pathogenic E. coli O157:H7, proteomic experiments revealed that AI-2 regulated the expression of multiple proteins involved in diverse metabolic processes playing important roles in bacterial virulence, such as adaptation, protection, cell motility, secretion, envelope biogenesis, and protein translation [132].
4.3. 4-Deoxy DPD (Laurencione), an MEP Pathway Byproduct
The MEP pathway is a major pathway elucidated in the 1990s [133]. During experiments deciphering its seven enzymatic steps [11], when pyruvate and ᴅ-glyceraldehyde were incubated with cell-free systems from E. coli or Klebsiella planticola, the authors observed not only the production of 1-deoxy-ᴅ-xylulose 73 (DX) but also of a compound identified as laurencione 74, first isolated in the red alga Laurencia spectabilis [134]. Algae are known for producing a huge number of small molecules whose physiological or ecological functions are unknown. Labeling experiments determined the origin of the laurencione carbon atoms indicating that laurencione and DX carbon skeletons resulted from the same condensation reaction and that laurencione was synthesized from DX by elimination of a water molecule (Scheme 3). The dehydratase involved in this reaction is yet unknown.
Strikingly, the molecular structure of laurencione 74 (4-deoxy-DPD) is very similar to that of DPD 68. Thus, besides the potential role of laurencione in isoprenoid metabolism, one can ask about its functions in cell–cell communication.
In V. harveyi, AI-2 signaling controls bioluminescence [126]. In the V. harveyi MM30 mutant, unable to synthesize AI-2, the addition of AI-2 restored the quorum signal and luminescence. A similar effect was observed after the addition of laurencione, yet with a 1000-fold lower efficiency [135]. This result showed that the substrate-sensor complex is certainly impacted by the absence of the hydroxyl group at the C4 position.
In E. coli JB525 mutant, which synthesizes an unstable green fluorescent protein in response to C6- and C8-N-acyl homoserine lactone 75, laurencione 74 as well as laurencione mono- and diacetate 76, 77 (Figure 11) reduced fluorescence by 50% at 600 µM, 150 µM, and 55 µM respectively. Additionally, these three compounds demonstrated anti-inflammatory activities, inhibiting nitric oxide production in lipopolysaccharide (LPS)-stimulated macrophages [136].
From these rather scarce experiments, it is clear that laurencione may be involved in cell communication, probably as an imperfect DPD mimic.
5. Conclusions and Remarks
Since the elucidation of the MEP pathway in the early 1990s, its potential as a selective drug target has been the focus of numerous publications. Of the seven enzymes involved, three-i.e., DXS, the best-studied DXR, and IspH-have gained much attention in antimicrobial development. Nevertheless, all the MEP enzymes present drawbacks to the design of inhibitors. As most of the MEP pathway intermediates are phosphorylated, catalytic pockets are polar, and therefore they can accommodate charged phosphate moieties, whereas the ligand design often requires a high degree of lipophilicity. Moreover, targeting general cofactors, such as the IspH Fe–S cluster, is attractive but hazardous, as it may lead to unexpected cytotoxicity. Considering targeting allosteric pockets may seem an elegant way to overcome these downsides, even though it appears to be even more challenging [9]. Additionally, the amino acid sequence of the enzymes from diverse bacteria can differ significantly, making the problem of universal inhibitor design evermore difficult to solve. Moreover, because of the scarcity of crystal structures for IspH and IspG, their inhibitors are tested on enzymes originating from extremophile bacteria, e.g., T. thermophilus or A. aeolicus. In vivo tests of bioavailable prodrugs of these inhibitors, especially on pathogenic bacteria, would be a welcome addition in the near future.
Another attractive facet of the MEP pathway is the synthesis of a potent phosphoantigen by its antepenultimate enzyme, IspG. While MEP pathway enzymes can be used as targets for antibacterial compounds, this same pathway could trigger γδ T-cell production, which plays critical roles in the early response to invasive pathogensAs bacteria in tumors have been shown to degrade the antitumor agent gemcitabine [137,138], we can capitalize on this dual opportunity to design new prodrugs for use in anticancer treatment which would act on both fronts: neutralizing bacteria as well as inducing an immune response in the host organism.
As all things come in threes, the MEP pathway could still hold surprises. Indeed, the small five-carbon chemical compound identified as a by-product of the pathway deserves consideration. Laurencione, or 4-deoxy-2,3-pentanedione, is structurally similar to the well-known signal molecule DPD, raising questions about its potential roles in quorum-sensing mechanisms or, more broadly, in cell–cell communication. To date, few insights have been made on this matter, but they tend to suggest that laurencione is really involved in these mechanisms. Understanding the mode of action of these signal molecules to disrupt these communications mechanisms may give new opportunities to design innovative antimicrobials.
Besides the synthesis of the small building blocks for isoprenoids, the MEP pathway cellular roles appear to be much more complex than previously thought, especially as the regulation of the MEP pathway is not fully understood. All these observations suggest that “cryptic” functions, i.e., phosphoantigen and laurencione syntheses, work side by side with the main function of the MEP pathway.
With regard to the importance of this pathway, questions worth asking still remain. Could there not be any other by-products of the MEP pathway with important cellular roles? How does regulation of the MEP pathway impact the metabolic flux of all its metabolites?
Writing—original draft preparation, T.P., A.A., D.L., M.R. and C.G.-B.; writing—review and editing, T.P., A.A., D.L., M.R. and C.G.-B. All authors have read and agreed to the published version of the manuscript.
Not applicable.
Not applicable.
Not applicable.
M.R. and C.G.-B. acknowledge the ”Frontier Research of Chemistry” foundation (Strasbourg, France) for financial support. A.A. acknowledges financial support from the ”Ministère de l’enseignement supérieur et de la Recherche”. The authors thank Cecylia Piechowiak contribution to proofreading the manuscript.
The authors declare no conflict of interest.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Enlarge this image.Scheme 1. The multifaceted MEP pathway. ThDP: thiamine diphosphate; PLP: pyridoxal phosphate; ᴅ-G3P: ᴅ-glyceraldehyde 3-phosphate; DXS: 1-deoxy-ᴅ-xylulose 5-phosphate synthase; DXP ; IspC: 1-deoxy-ᴅ-xylulose 5-phosphate reductoisomerase; MEP: 2-C-methyl-ᴅ-erythritol 4-phosphate; IspD: 2-C-methyl-ᴅ-erythritol 4-phosphate cytidyl transferase; CDP-ME: 4-diphosphocytidyl-2-C-methyl-ᴅ-erythritol; IspF: 2-C-methyl-ᴅ-erythritol 2,4-cyclodiphosphate synthase; MEcPP: 2-C-methyl-ᴅ-erythritol-2,4 cyclodiphosphate; IspG: 2-C-methyl-ᴅ-erythritol 2,4-cyclodiphosphate reductase; HMBPP: (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate; IspH: 4-hydroxy-3-methylbut-2-enyl diphosphate reductase; DMAPP: dimethylallyl diphosphate; IPP: isopentenyl diphosphate.
Enlarge this image.Figure 1. Representative inhibitors of DXS. IC50: half maximal inhibitory concentration; MIC: minimum inhibitory concentration; Ki: inhibitory constant.
Enlarge this image.Figure 8. Natural phosphoantigens from the isoprenoid biosynthesis and aminobisphosphonates. MVA: mevalonate; EC50: half maximal effective concentration.
Enlarge this image.Scheme 2. (A) DPD as a precursor to AI-2 S-(tetrahydroxytetrahydrofuran)-borate diester (S-THMF-borate) (B) DPD analogs.
References
1. Rohmer, M.; Knani, M.; Simonin, P.; Sutter, B.; Sahm, H. Isoprenoid biosynthesis in bacteria: A novel pathway for the early steps leading to isopentenyl diphosphate. Biochem. J.; 1993; 295, pp. 517-524. [DOI: https://dx.doi.org/10.1042/bj2950517] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8240251]
2. Lombard, J.; Moreira, D. Origins and early evolution of the mevalonate pathway of isoprenoid biosynthesis in the three domains of Life. Mol. Biol. Evol.; 2011; 28, pp. 87-99. [DOI: https://dx.doi.org/10.1093/molbev/msq177] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20651049]
3. Rohmer, M. The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria, algae and higher plants. Nat. Prod. Rep.; 1999; 16, pp. 565-574. [DOI: https://dx.doi.org/10.1039/a709175c] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10584331]
4. Frank, A.; Groll, M. The methylerythritol phosphate pathway to isoprenoids. Chem. Rev.; 2017; 117, pp. 5675-5703. [DOI: https://dx.doi.org/10.1021/acs.chemrev.6b00537]
5. Cane, D.E.; Du, S.; Robinson, J.K.; Hsiung, Y.; Spenser, I.D. Biosynthesis of vitamin B6: Enzymatic conversion of 1-deoxy-ᴅ-xylulose-5-phosphate to pyridoxol phosphate. J. Am. Chem. Soc.; 1999; 121, pp. 7722-7723. [DOI: https://dx.doi.org/10.1021/ja9914947]
6. Fitzpatrick, T.B.; Moccand, C.; Roux, C. Vitamin B6 biosynthesis: Charting the mechanistic landscape. ChemBioChem; 2010; 11, pp. 1185-1193. [DOI: https://dx.doi.org/10.1002/cbic.201000084]
7. David, S.; Estramareix, B.; Fischer, J.C.; Therisod, M. 1-Deoxy-ᴅ-threo-2-pentulose: The precursor of the five-carbon chain of the thiazole of thiamine. J. Am. Chem. Soc.; 1981; 103, pp. 7341-7342. [DOI: https://dx.doi.org/10.1021/ja00414a053]
8. Park, J.-H.; Dorrestein, P.C.; Zhai, H.; Kinsland, C.; McLafferty, F.W.; Begley, T.P. Biosynthesis of the thiazole moiety of thiamin pyrophosphate (Vitamin B1). Biochemistry; 2003; 42, pp. 12430-12438. [DOI: https://dx.doi.org/10.1021/bi034902z]
9. Masini, T.; Hirsch, A.K.H. Development of inhibitors of the 2-C-methyl-ᴅ-erythritol 4-phosphate (MEP) pathway enzymes as potential anti-infective agents. J. Med. Chem.; 2014; 57, pp. 9740-9763. [DOI: https://dx.doi.org/10.1021/jm5010978]
10. Altincicek, B.; Moll, J.; Campos, N.; Foerster, G.; Beck, E.; Hoeffler, J.-F.; Grosdemange-Billiard, C.; Rodríguez-Concepción, M.; Rohmer, M.; Boronat, A. et al. Cutting Edge: Human γδ T cells are activated by intermediates of the 2-C-methyl-ᴅ-erythritol 4-phosphate pathway of isoprenoid biosynthesis. J. Immunol.; 2001; 166, pp. 3655-3658. [DOI: https://dx.doi.org/10.4049/jimmunol.166.6.3655]
11. Rosa Putra, S.; Charon, L.; Danielsen, K.; Pale-Grosdemange, C.; Lois, L.-M.; Campos, N.; Boronat, A.; Rohmer, M. 5-Hydroxypentane-2,3-dione (laurencione), a bacterial metabolite of 1-deoxy-ᴅ-threo-pentulose. Tetrahedron Lett.; 1998; 39, pp. 6185-6188. [DOI: https://dx.doi.org/10.1016/S0040-4039(98)01301-X]
12. Hardie, K.R.; Heurlier, K. Establishing bacterial communities by “word of mouth”: LuxS and autoinducer 2 in biofilm development. Nat. Rev. Microbiol.; 2008; 6, pp. 635-643. [DOI: https://dx.doi.org/10.1038/nrmicro1916]
13. WHO Global Shortage of Innovative Antibiotics Fuels Emergence and Spread of Drug-Resistance. Available online: https://www.who.int/news/item/15-04-2021-global-shortage-of-innovative-antibiotics-fuels-emergence-and-spread-of-drug-resistance (accessed on 15 December 2022).
14. Xiang, S.; Usunow, G.; Lange, G.; Busch, M.; Tong, L. Crystal structure of 1-deoxy-ᴅ-xylulose 5-phosphate synthase, a crucial enzyme for isoprenoids biosynthesis. J. Biol. Chem.; 2007; 282, pp. 2676-2682. [DOI: https://dx.doi.org/10.1074/jbc.M610235200]
15. Bartee, D.; Freel Meyers, C.L. Toward understanding the chemistry and biology of 1-deoxy-ᴅ-xylulose 5-phosphate (DXP) synthase: A unique antimicrobial target at the heart of bacterial metabolism. Acc. Chem. Res.; 2018; 51, pp. 2546-2555. [DOI: https://dx.doi.org/10.1021/acs.accounts.8b00321]
16. Brammer Basta, L.A.; Patel, H.; Kakalis, L.; Jordan, F.; Freel Meyers, C.L. Defining critical residues for substrate binding to 1-deoxy-ᴅ-xylulose 5-phosphate synthase—active site substitutions stabilize the predecarboxylation intermediate C2α-lactylthiamin diphosphate. FEBS J.; 2014; 281, pp. 2820-2837. [DOI: https://dx.doi.org/10.1111/febs.12823]
17. Matsue, Y.; Mizuno, H.; Tomita, T.; Asami, T.; Nishiyama, M.; Kuzuyama, T. The herbicide ketoclomazone inhibits 1-deoxy-ᴅ-xylulose 5-phosphate synthase in the 2-C-methyl-ᴅ-erythritol 4-phosphate pathway and shows antibacterial activity against Haemophilus influenzae. J. Antibiot. (Tokyo); 2010; 63, pp. 583-588. [DOI: https://dx.doi.org/10.1038/ja.2010.100]
18. Hayashi, D.; Kato, N.; Kuzuyama, T.; Sato, Y.; Ohkanda, J. Antimicrobial N-(2-chlorobenzyl)-substituted hydroxamate is an inhibitor of 1-deoxy-ᴅ-xylulose 5-phosphate synthase. Chem. Commun.; 2013; 49, 5535. [DOI: https://dx.doi.org/10.1039/c3cc40758f]
19. Bartee, D.; Morris, F.; Al-khouja, A.; Freel Meyers, C.L. Hydroxybenzaldoximes are ᴅ-GAP-competitive inhibitors of E. coli 1-deoxy-ᴅ-xylulose-5-phosphate synthase. ChemBioChem; 2015; 16, pp. 1771-1781. [DOI: https://dx.doi.org/10.1002/cbic.201500119]
20. Smith, J.M.; Vierling, R.J.; Meyers, C.F. Selective inhibition of E. coli 1-deoxy-ᴅ-xylulose-5-phosphate synthase by acetylphosphonates. Med Chem Commun; 2012; 3, pp. 65-67. [DOI: https://dx.doi.org/10.1039/C1MD00233C]
21. Smith, J.M.; Warrington, N.V.; Vierling, R.J.; Kuhn, M.L.; Anderson, W.F.; Koppisch, A.T.; Freel Meyers, C.L. Targeting DXP synthase in human pathogens: Enzyme inhibition and antimicrobial activity of butylacetylphosphonate. J. Antibiot. (Tokyo); 2014; 67, pp. 77-83. [DOI: https://dx.doi.org/10.1038/ja.2013.105]
22. Bartee, D.; Freel Meyers, C.L. Targeting the unique mechanism of bacterial 1-deoxy-ᴅ-xylulose-5-phosphate synthase. Biochemistry; 2018; 57, pp. 4349-4356. [DOI: https://dx.doi.org/10.1021/acs.biochem.8b00548] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29944345]
23. Bartee, D.; Sanders, S.; Phillips, P.D.; Harrison, M.J.; Koppisch, A.T.; Freel Meyers, C.L. Enamide prodrugs of acetyl phosphonate deoxy-ᴅ-xylulose-5-phosphate synthase inhibitors as potent antibacterial agents. ACS Infect. Dis.; 2019; 5, pp. 406-417. [DOI: https://dx.doi.org/10.1021/acsinfecdis.8b00307] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30614674]
24. Masini, T.; Lacy, B.; Monjas, L.; Hawksley, D.; de Voogd, A.R.; Illarionov, B.; Iqbal, A.; Leeper, F.J.; Fischer, M.; Kontoyianni, M. et al. Validation of a homology model of Mycobacterium tuberculosis DXS: Rationalization of observed activities of thiamine derivatives as potent inhibitors of two orthologues of DXS. Org. Biomol. Chem.; 2015; 13, pp. 11263-11277. [DOI: https://dx.doi.org/10.1039/C5OB01666E] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26411373]
25. Kuzuyama, T.; Shimizu, T.; Takahashi, S.; Seto, H. Fosmidomycin, a specific inhibitor of 1-deoxy-ᴅ-xylulose 5-phosphate reductoisomerase in the nonmevalonate pathway for terpenoid biosynthesis. Tetrahedron Lett.; 1998; 39, pp. 7913-7916. [DOI: https://dx.doi.org/10.1016/S0040-4039(98)01755-9]
26. Kuntz, L.; Tritsch, D.; Grosdemange-Billiard, C.; Hemmerlin, A.; Willem, A.; Bach, T.J.; Rohmer, M. Isoprenoid biosynthesis as a target for antibacterial and antiparasitic drugs: Phosphonohydroxamic acids as inhibitors of deoxyxylulose phosphate reducto-isomerase. Biochem. J.; 2005; 386, pp. 127-135. [DOI: https://dx.doi.org/10.1042/BJ20041378]
27. Munier, M.; Tritsch, D.; Lièvremont, D.; Rohmer, M.; Grosdemange-Billiard, C. Synthesis and biological evaluation of aryl phosphoramidate prodrugs of fosfoxacin and its derivatives. Bioorganic Chem.; 2019; 89, 103012. [DOI: https://dx.doi.org/10.1016/j.bioorg.2019.103012]
28. Sakamoto, Y.; Furukawa, S.; Ogihara, H.; Yamasaki, M. Fosmidomycin resistance in adenylate cyclase deficient (cya) mutants of Escherichia coli. Biosci. Biotechnol. Biochem.; 2003; 67, pp. 2030-2033. [DOI: https://dx.doi.org/10.1271/bbb.67.2030]
29. Dhiman, R.K.; Schaeffer, M.L.; Bailey, A.M.; Testa, C.A.; Scherman, H.; Crick, D.C. 1-Deoxy-ᴅ-xylulose 5-phosphate reductoisomerase (IspC) from Mycobacterium tuberculosis: Towards understanding mycobacterial resistance to fosmidomycin. J. Bacteriol.; 2005; 187, pp. 8395-8402. [DOI: https://dx.doi.org/10.1128/JB.187.24.8395-8402.2005]
30. Na-Bangchang, K.; Ruengweerayut, R.; Karbwang, J.; Chauemung, A.; Hutchinson, D. Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria. Malar. J.; 2007; 6, 70. [DOI: https://dx.doi.org/10.1186/1475-2875-6-70]
31. Piselli, C.; Benz, R. Fosmidomycin transport through the phosphate-specific porins OprO and OprP of Pseudomonas aeruginosa. Mol. Microbiol.; 2021; 116, pp. 97-108. [DOI: https://dx.doi.org/10.1111/mmi.14693]
32. Katayama, N.; Tsubotani, S.; Nozaki, Y.; Harada, S.; Ono, H. Fosfadecin and fosfocytocin, new nucleotide antibiotics produced by bacteria. J. Antibiot. (Tokyo); 1990; 43, pp. 238-246. [DOI: https://dx.doi.org/10.7164/antibiotics.43.238]
33. Woo, Y.-H.; Fernandes, R.P.M.; Proteau, P.J. Evaluation of fosmidomycin analogs as inhibitors of the Synechocystis sp. PCC6803 1-deoxy-ᴅ-xylulose 5-phosphate reductoisomerase. Bioorg. Med. Chem.; 2006; 14, pp. 2375-2385. [DOI: https://dx.doi.org/10.1016/j.bmc.2005.11.012]
34. Munier, M. Synthèse de Prodrogues d’inhibiteurs de la 1-désoxy-ᴅ-xylulose 5-phosphate Réductoisomérase (DXR) : Des Agents Antituberculeux Potentiels. Ph.D. Thesis; Université de Strasbourg: Strasbourg, France, 2016.
35. Jackson, E.R.; San Jose, G.; Brothers, R.C.; Edelstein, E.K.; Sheldon, Z.; Haymond, A.; Johny, C.; Boshoff, H.I.; Couch, R.D.; Dowd, C.S. The effect of chain length and unsaturation on Mtb Dxr inhibition and antitubercular killing activity of FR900098 analogs. Bioorg. Med. Chem. Lett.; 2014; 24, pp. 649-653. [DOI: https://dx.doi.org/10.1016/j.bmcl.2013.11.067]
36. Chofor, R.; Risseeuw, M.; Pouyez, J.; Johny, C.; Wouters, J.; Dowd, C.; Couch, R.; Van Calenbergh, S. Synthetic fosmidomycin analogues with altered chelating moieties do not inhibit 1-deoxy-ᴅ-xylulose 5-phosphate reductoisomerase or Plasmodium falciparum growth in vitro. Molecules; 2014; 19, pp. 2571-2587. [DOI: https://dx.doi.org/10.3390/molecules19022571]
37. Andaloussi, M.; Lindh, M.; Björkelid, C.; Suresh, S.; Wieckowska, A.; Iyer, H.; Karlén, A.; Larhed, M. Substitution of the phosphonic acid and hydroxamic acid functionalities of the DXR inhibitor FR900098: An attempt to improve the activity against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett.; 2011; 21, pp. 5403-5407. [DOI: https://dx.doi.org/10.1016/j.bmcl.2011.07.005]
38. Ponaire, S.; Zinglé, C.; Tritsch, D.; Grosdemange-Billiard, C.; Rohmer, M. Growth inhibition of Mycobacterium smegmatis by prodrugs of deoxyxylulose phosphate reducto-isomerase inhibitors, promising anti-mycobacterial agents. Eur. J. Med. Chem.; 2012; 51, pp. 277-285. [DOI: https://dx.doi.org/10.1016/j.ejmech.2012.02.031]
39. Munier, M.; Tritsch, D.; Krebs, F.; Esque, J.; Hemmerlin, A.; Rohmer, M.; Stote, R.H.; Grosdemange-Billiard, C. Synthesis and biological evaluation of phosphate isosters of fosmidomycin and analogs as inhibitors of Escherichia coli and Mycobacterium smegmatis 1-deoxyxylulose 5-phosphate reductoisomerases. Bioorg. Med. Chem.; 2017; 25, pp. 684-689. [DOI: https://dx.doi.org/10.1016/j.bmc.2016.11.040]
40. Dreneau, A.; Krebs, F.S.; Munier, M.; Ngov, C.; Tritsch, D.; Lièvremont, D.; Rohmer, M.; Grosdemange-Billiard, C. α,α-Difluorophosphonohydroxamic acid derivatives among the best antibacterial fosmidomycin analogues. Molecules; 2021; 26, 5111. [DOI: https://dx.doi.org/10.3390/molecules26165111]
41. Xue, J.; Diao, J.; Cai, G.; Deng, L.; Zheng, B.; Yao, Y.; Song, Y. Antimalarial and structural studies of pyridine-containing inhibitors of 1-deoxyxylulose-5-phosphate reductoisomerase. ACS Med. Chem. Lett.; 2013; 4, pp. 278-282. [DOI: https://dx.doi.org/10.1021/ml300419r]
42. Haemers, T.; Wiesner, J.; Poecke, S.V.; Goeman, J.; Henschker, D.; Beck, E.; Jomaa, H.; Calenbergh, S.V. Synthesis of α-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors. Bioorg. Med. Chem. Lett.; 2006; 16, pp. 1888-1891. [DOI: https://dx.doi.org/10.1016/j.bmcl.2005.12.082]
43. Kunfermann, A.; Lienau, C.; Illarionov, B.; Held, J.; Gräwert, T.; Behrendt, C.T.; Werner, P.; Hähn, S.; Eisenreich, W.; Riederer, U. et al. IspC as target for antiinfective drug discovery: Synthesis, enantiomeric separation, and structural biology of fosmidomycin thia isosters. J. Med. Chem.; 2013; 56, pp. 8151-8162. [DOI: https://dx.doi.org/10.1021/jm4012559] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24032981]
44. Ball, H.S.; Girma, M.; Zainab, M.; Riley, H.; Behrendt, C.T.; Lienau, C.; Konzuch, S.; Avelar, L.A.A.; Lungerich, B.; Soojhawon, I. et al. Inhibition of the Yersinia pestis methylerythritol phosphate pathway of isoprenoid biosynthesis by α-phenyl-substituted reverse fosmidomycin analogues. ACS Omega; 2020; 5, pp. 5170-5175. [DOI: https://dx.doi.org/10.1021/acsomega.9b04171] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32201804]
45. San Jose, G.; Jackson, E.R.; Haymond, A.; Johny, C.; Edwards, R.L.; Wang, X.; Brothers, R.C.; Edelstein, E.K.; Odom, A.R.; Boshoff, H.I. et al. Structure–activity relationships of the MEPicides: N-Acyl and O-Linked analogs of FR900098 as inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis. ACS Infect. Dis.; 2016; 2, pp. 923-935. [DOI: https://dx.doi.org/10.1021/acsinfecdis.6b00125] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27676224]
46. McKenney, E.S.; Sargent, M.; Khan, H.; Uh, E.; Jackson, E.R.; Jose, G.S.; Couch, R.D.; Dowd, C.S.; van Hoek, M.L. Lipophilic prodrugs of FR900098 are antimicrobial against Francisella novicida in vivo and in vitro and show GlpT independent efficacy. PLoS ONE; 2012; 7, e38167. [DOI: https://dx.doi.org/10.1371/journal.pone.0038167] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23077474]
47. Brown, A.C.; Parish, T. Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake. BMC Microbiol.; 2008; 8, 78. [DOI: https://dx.doi.org/10.1186/1471-2180-8-78]
48. Uh, E.; Jackson, E.R.; San Jose, G.; Maddox, M.; Lee, R.E.; Lee, R.E.; Boshoff, H.I.; Dowd, C.S. Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs. Bioorg. Med. Chem. Lett.; 2011; 21, pp. 6973-6976. [DOI: https://dx.doi.org/10.1016/j.bmcl.2011.09.123]
49. Courtens, C.; Risseeuw, M.; Caljon, G.; Maes, L.; Martin, A.; Van Calenbergh, S. Amino acid based prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents. Bioorg. Med. Chem.; 2019; 27, pp. 729-747. [DOI: https://dx.doi.org/10.1016/j.bmc.2019.01.016]
50. Courtens, C.; Risseeuw, M.; Caljon, G.; Maes, L.; Cos, P.; Martin, A.; Van Calenbergh, S. Double prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents. Bioorg. Med. Chem. Lett.; 2019; 29, pp. 1232-1235. [DOI: https://dx.doi.org/10.1016/j.bmcl.2019.03.009]
51. Kuzuyama, T.; Takagi†, M.; Kaneda, K.; Dairi, T.; Seto, H. Formation of 4-(cytidine 5′-diphospho)-2-C-methyl-ᴅ-erythritol from 2-C-methyl-ᴅ-erythritol 4-phosphate by 2-C-methyl-ᴅ-erythritol 4-phosphate cytidylyltransferase, a new enzyme in the nonmevalonate pathway. Tetrahedron Lett.; 2000; 41, pp. 703-706. [DOI: https://dx.doi.org/10.1016/S0040-4039(99)02143-7]
52. Rohdich, F.; Wungsintaweekul, J.; Fellermeier, M.; Sagner, S.; Herz, S.; Kis, K.; Eisenreich, W.; Bacher, A.; Zenk, M.H. Cytidine 5′-triphosphate-dependent biosynthesis of isoprenoids: YgbP protein of Escherichia coli catalyzes the formation of 4-diphosphocytidyl-2-C-methylerythritol. Proc. Natl. Acad. Sci. USA; 1999; 96, pp. 11758-11763. [DOI: https://dx.doi.org/10.1073/pnas.96.21.11758]
53. Schwab, A.; Illarionov, B.; Frank, A.; Kunfermann, A.; Seet, M.; Bacher, A.; Witschel, M.C.; Fischer, M.; Groll, M.; Diederich, F. Mechanism of allosteric inhibition of the enzyme IspD by three different classes of ligands. ACS Chem. Biol.; 2017; 12, pp. 2132-2138. [DOI: https://dx.doi.org/10.1021/acschembio.7b00004]
54. Riemersma, M.; Froese, D.S.; van Tol, W.; Engelke, U.F.; Kopec, J.; van Scherpenzeel, M.; Ashikov, A.; Krojer, T.; von Delft, F.; Tessari, M. et al. Human ISPD is a cytidyltransferase required for dystroglycan O-mannosylation. Chem. Biol.; 2015; 22, pp. 1643-1652. [DOI: https://dx.doi.org/10.1016/j.chembiol.2015.10.014]
55. Bavin, E.M.; Kay, E.; Simmonite, D. Some observations on the activity of mixtures of antibacterial substances. J. Pharm. Pharmacol.; 2011; 7, pp. 676-682. [DOI: https://dx.doi.org/10.1111/j.2042-7158.1955.tb12080.x]
56. Gao, P.; Yang, Y.; Xiao, C.; Liu, Y.; Gan, M.; Guan, Y.; Hao, X.; Meng, J.; Zhou, S.; Chen, X. et al. Identification and validation of a novel lead compound targeting 4-diphosphocytidyl-2-C-methylerythritol synthetase (IspD) of mycobacteria. Eur. J. Pharmacol.; 2012; 694, pp. 45-52. [DOI: https://dx.doi.org/10.1016/j.ejphar.2012.08.012]
57. Bartee, D.; Wheadon, M.J.; Freel Meyers, C.L. Synthesis and evaluation of fluoroalkyl phosphonyl analogues of 2-C-methylerythritol phosphate as substrates and inhibitors of IspD from human pathogens. J. Org. Chem.; 2018; 83, pp. 9580-9591. [DOI: https://dx.doi.org/10.1021/acs.joc.8b00686]
58. Lillo, A.M.; Tetzlaff, C.N.; Sangari, F.J.; Cane, D.E. Functional expression and characterization of eryA, the erythritol kinase of Brucella abortus, and enzymatic synthesis of l-erythritol-4-phosphate. Bioorg. Med. Chem. Lett.; 2003; 13, pp. 737-739. [DOI: https://dx.doi.org/10.1016/S0960-894X(02)01032-6]
59. Ershov, Y.V. 2-C-methylerythritol phosphate pathway of isoprenoid biosynthesis as a target in identifying new antibiotics, herbicides, and immunomodulators: A review. Appl. Biochem. Microbiol.; 2007; 43, pp. 115-138. [DOI: https://dx.doi.org/10.1134/S0003683807020019]
60. Baatarkhuu, Z.; Chaignon, P.; Borel, F.; Ferrer, J.-L.; Wagner, A.; Seemann, M. Synthesis and kinetic evaluation of an azido analogue of methylerythritol phosphate: A novel inhibitor of E. coli YgbP/IspD. Sci. Rep.; 2018; 8, 17892. [DOI: https://dx.doi.org/10.1038/s41598-018-35586-y]
61. Zhang, B.; Watts, K.M.; Hodge, D.; Kemp, L.M.; Hunstad, D.A.; Hicks, L.M.; Odom, A.R. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling. Biochemistry; 2011; 50, pp. 3570-3577. [DOI: https://dx.doi.org/10.1021/bi200113y]
62. Eoh, H.; Narayanasamy, P.; Brown, A.C.; Parish, T.; Brennan, P.J.; Crick, D.C. Expression and characterization of soluble 4-diphosphocytidyl-2-C-methyl-ᴅ-erythritol kinase from bacterial pathogens. Chem. Biol.; 2009; 16, pp. 1230-1239. [DOI: https://dx.doi.org/10.1016/j.chembiol.2009.10.014]
63. Sgraja, T.; Alphey, M.S.; Ghilagaber, S.; Marquez, R.; Robertson, M.N.; Hemmings, J.L.; Lauw, S.; Rohdich, F.; Bacher, A.; Eisenreich, W. et al. Characterization of Aquifex aeolicus 4-diphosphocytidyl-2-C-methyl-ᴅ-erythritol kinase—ligand recognition in a template for antimicrobial drug discovery: Aquifex aeolicus IspE. FEBS J.; 2008; 275, pp. 2779-2794. [DOI: https://dx.doi.org/10.1111/j.1742-4658.2008.06418.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18422643]
64. Schütz, A.P.; Locher, S.; Bernet, B.; Illarionov, B.; Fischer, M.; Bacher, A.; Diederich, F. 5-Substituted (1-thiolan-2-yl)cytosines as inhibitors of A. aeolicus and E. coli IspE kinases: Very different affinities to similar substrate-binding sites: Inhibitors of A. aeolicus and E. coli IspE kinases. Eur. J. Org. Chem.; 2013; 2013, pp. 880-887. [DOI: https://dx.doi.org/10.1002/ejoc.201201454]
65. Hirsch, A.K.H.; Lauw, S.; Gersbach, P.; Schweizer, W.B.; Rohdich, F.; Eisenreich, W.; Bacher, A.; Diederich, F. Nonphosphate inhibitors of IspE protein, a kinase in the non-mevalonate pathway for isoprenoid biosynthesis and a potential target for antimalarial therapy. ChemMedChem; 2007; 2, pp. 806-810. [DOI: https://dx.doi.org/10.1002/cmdc.200700014] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17361977]
66. Hirsch, A.K.H.; Diederich, F.; Antonietti, M.; Börner, H.G. Bioconjugates to specifically render inhibitors water-soluble. Soft Matter; 2010; 6, pp. 88-91. [DOI: https://dx.doi.org/10.1039/B915928B]
67. Tang, M.; Odejinmi, S.I.; Allette, Y.M.; Vankayalapati, H.; Lai, K. Identification of novel small molecule inhibitors of 4-diphosphocytidyl-2-C-methyl-ᴅ-erythritol (CDP-ME) kinase of Gram-negative bacteria. Bioorg. Med. Chem.; 2011; 19, pp. 5886-5895. [DOI: https://dx.doi.org/10.1016/j.bmc.2011.08.012] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21903402]
68. Steinbacher, S.; Kaiser, J.; Wungsintaweekul, J.; Hecht, S.; Eisenreich, W.; Gerhardt, S.; Bacher, A.; Rohdich, F. Structure of 2-C-methyl-ᴅ-erythritol-2,4-cyclodiphosphate synthase involved in mevalonate-independent biosynthesis of isoprenoids. J. Mol. Biol.; 2002; 316, pp. 79-88. [DOI: https://dx.doi.org/10.1006/jmbi.2001.5341]
69. Kemp, L.E.; Alphey, M.S.; Bond, C.S.; Ferguson, M.A.J.; Hecht, S.; Bacher, A.; Eisenreich, W.; Rohdich, F.; Hunter, W.N. The identification of isoprenoids that bind in the intersubunit cavity of Escherichia coli 2-C-methyl-ᴅ-erythritol-2,4-cyclodiphosphate synthase by complementary biophysical methods. Acta Crystallogr. D Biol. Crystallogr.; 2005; 61, pp. 45-52. [DOI: https://dx.doi.org/10.1107/S0907444904025971]
70. Bitok, J.K.; Meyers, C.F. 2-C-Methyl-ᴅ-erythritol 4-phosphate enhances and sustains cyclodiphosphate synthase IspF activity. ACS Chem. Biol.; 2012; 7, pp. 1702-1710. [DOI: https://dx.doi.org/10.1021/cb300243w]
71. Kipchirchir Bitok, J.; Meyers, C.F. Synthesis and evaluation of stable substrate analogs as potential modulators of cyclodiphosphate synthase IspF. MedChemComm; 2013; 4, pp. 130-134. [DOI: https://dx.doi.org/10.1039/C2MD20175E]
72. Geist, J.G.; Lauw, S.; Illarionova, V.; Illarionov, B.; Fischer, M.; Gräwert, T.; Rohdich, F.; Eisenreich, W.; Kaiser, J.; Groll, M. et al. Thiazolopyrimidine inhibitors of 2-methylerythritol 2,4-cyclodiphosphate synthase (IspF) from Mycobacterium tuberculosis and Plasmodium falciparum. ChemMedChem; 2010; 5, pp. 1092-1101. [DOI: https://dx.doi.org/10.1002/cmdc.201000083]
73. Thelemann, J.; Illarionov, B.; Barylyuk, K.; Geist, J.; Kirchmair, J.; Schneider, P.; Anthore, L.; Root, K.; Trapp, N.; Bacher, A. et al. Aryl bis-sulfonamide inhibitors of IspF from Arabidopsis thaliana and Plasmodium falciparum. ChemMedChem; 2015; 10, pp. 2090-2098. [DOI: https://dx.doi.org/10.1002/cmdc.201500382]
74. Root, K.; Barylyuk, K.; Schwab, A.; Thelemann, J.; Illarionov, B.; Geist, J.G.; Gräwert, T.; Bacher, A.; Fischer, M.; Diederich, F. et al. Aryl bis-sulfonamides bind to the active site of a homotrimeric isoprenoid biosynthesis enzyme IspF and extract the essential divalent metal cation cofactor. Chem. Sci.; 2018; 9, pp. 5976-5986. [DOI: https://dx.doi.org/10.1039/C8SC00814K]
75. Liu, Z.; Jin, Y.; Liu, W.; Tao, Y.; Wang, G. Crystal structure of IspF from Bacillus subtilis and absence of protein complex assembly amongst IspD/IspE/IspF enzymes in the MEP pathway. Biosci. Rep.; 2018; 38, BSR20171370. [DOI: https://dx.doi.org/10.1042/BSR20171370]
76. Honold, A.; Lettl, C.; Schindele, F.; Illarionov, B.; Haas, R.; Witschel, M.; Bacher, A.; Fischer, M. Inhibitors of the bifunctional 2-C-methyl-
77. Quitterer, F.; Frank, A.; Wang, K.; Rao, G.; O’Dowd, B.; Li, J.; Guerra, F.; Abdel-Azeim, S.; Bacher, A.; Eppinger, J. et al. Atomic-resolution structures of discrete stages on the reaction coordinate of the [Fe4-S4] enzyme IspG (GcpE). J. Mol. Biol.; 2015; 427, pp. 2220-2228. [DOI: https://dx.doi.org/10.1016/j.jmb.2015.04.002]
78. Rekittke, I.; Jomaa, H.; Ermler, U. Structure of the GcpE (IspG)-MEcPP complex from Thermus thermophilus. FEBS Lett.; 2012; 586, pp. 3452-3457. [DOI: https://dx.doi.org/10.1016/j.febslet.2012.07.070]
79. Liu, Y.-L.; Guerra, F.; Wang, K.; Wang, W.; Li, J.; Huang, C.; Zhu, W.; Houlihan, K.; Li, Z.; Zhang, Y. et al. Structure, function and inhibition of the two- and three-domain 4Fe-4S IspG proteins. Proc. Natl. Acad. Sci. USA; 2012; 109, pp. 8558-8563. [DOI: https://dx.doi.org/10.1073/pnas.1121107109]
80. Wang, W.; Li, J.; Wang, K.; Huang, C.; Zhang, Y.; Oldfield, E. Organometallic mechanism of action and inhibition of the 4Fe-4S isoprenoid biosynthesis protein GcpE (IspG). Proc. Natl. Acad. Sci. USA; 2010; 107, pp. 11189-11193. [DOI: https://dx.doi.org/10.1073/pnas.1000264107]
81. Lee, M.; Gräwert, T.; Quitterer, F.; Rohdich, F.; Eppinger, J.; Eisenreich, W.; Bacher, A.; Groll, M. Biosynthesis of isoprenoids: Crystal structure of the [4Fe-4S] cluster protein IspG. J. Mol. Biol.; 2010; 404, pp. 600-610. [DOI: https://dx.doi.org/10.1016/j.jmb.2010.09.050]
82. Masini, T.; Kroezen, B.S.; Hirsch, A.K.H. Druggability of the enzymes of the non-mevalonate pathway. Drug Discov. Today; 2013; 18, pp. 1256-1262. [DOI: https://dx.doi.org/10.1016/j.drudis.2013.07.003]
83. Janthawornpong, K.; Krasutsky, S.; Chaignon, P.; Rohmer, M.; Poulter, C.D.; Seemann, M. Inhibition of IspH, a [4Fe-4S]2+ enzyme involved in the biosynthesis of isoprenoids via the methylerythritol phosphate pathway. J. Am. Chem. Soc.; 2013; 135, pp. 1816-1822. [DOI: https://dx.doi.org/10.1021/ja309557s] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23316732]
84. Guerra, F.; Wang, K.; Li, J.; Wang, W.; Liu, Y.-L.; Amin, S.; Oldfield, E. Inhibition of the 4Fe–4S proteins IspG and IspH: An EPR, ENDOR and HYSCORE investigation. Chem. Sci.; 2014; 5, pp. 1642-1649. [DOI: https://dx.doi.org/10.1039/C3SC53301H] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24999381]
85. Wang, K.; Wang, W.; No, J.-H.; Zhang, Y.; Zhang, Y.; Oldfield, E. Inhibition of the Fe4S4-cluster-containing protein IspH (LytB): Electron Paramagnetic Resonance, metallacycles, and mechanisms. J. Am. Chem. Soc.; 2010; 132, pp. 6719-6727. [DOI: https://dx.doi.org/10.1021/ja909664j] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20426416]
86. O’Dowd, B.; Williams, S.; Wang, H.; No, J.H.; Rao, G.; Wang, W.; McCammon, J.A.; Cramer, S.P.; Oldfield, E. Spectroscopic and computational investigations of ligand binding to IspH: Discovery of non-diphosphate inhibitors. ChemBioChem; 2017; 18, pp. 914-920. [DOI: https://dx.doi.org/10.1002/cbic.201700052]
87. Tanaka, Y.; Sano, S.; Nieves, E.; De Libero, G.; Rosa, D.; Modlin, R.L.; Brenner, M.B.; Bloom, B.R.; Morita, C.T. Nonpeptide ligands for human gamma delta T cells. Proc. Natl. Acad. Sci. USA; 1994; 91, pp. 8175-8179. [DOI: https://dx.doi.org/10.1073/pnas.91.17.8175]
88. Dimova, T.; Brouwer, M.; Gosselin, F.; Tassignon, J.; Leo, O.; Donner, C.; Marchant, A.; Vermijlen, D. Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire. Proc. Natl. Acad. Sci. USA; 2015; 112, pp. E556-E565. [DOI: https://dx.doi.org/10.1073/pnas.1412058112]
89. Herrmann, T.; Karunakaran, M.M.; Fichtner, A.S. A glance over the fence: Using phylogeny and species comparison for a better understanding of antigen recognition by human γδ T-cells. Immunol. Rev.; 2020; 298, pp. 218-236. [DOI: https://dx.doi.org/10.1111/imr.12919]
90. Bonneville, M.; O’Brien, R.L.; Born, W.K. γδ T cell effector functions: A blend of innate programming and acquired plasticity. Nat. Rev. Immunol.; 2010; 10, pp. 467-478. [DOI: https://dx.doi.org/10.1038/nri2781]
91. Riganti, C.; Massaia, M.; Davey, M.S.; Eberl, M. Human γδ T-cell responses in infection and immunotherapy: Common mechanisms, common mediators? Highlights. Eur. J. Immunol.; 2012; 42, pp. 1668-1676. [DOI: https://dx.doi.org/10.1002/eji.201242492]
92. Harly, C.; Peigné, C.-M.; Scotet, E. Molecules and mechanisms implicated in the peculiar antigenic activation process of human Vγ9Vδ2 T cells. Front. Immunol.; 2015; 5, pp. 1-13. [DOI: https://dx.doi.org/10.3389/fimmu.2014.00657]
93. Tanaka, Y.; Moritat, C.T.; Tanaka, Y.; Nievest, E.; Brennert, M.B.; Bloom, B.R. Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature; 1995; 375, pp. 155-158. [DOI: https://dx.doi.org/10.1038/375155a0]
94. Espinosa, E.; Belmant, C.; Sicard, H.; Poupot, R.; Bonneville, M.; Fournié, J.-J. Y2K+1 state-of-the-art on non-peptide phosphoantigens, a novel category of immunostimulatory molecules. Microbes Infect.; 2001; 3, pp. 645-654. [DOI: https://dx.doi.org/10.1016/S1286-4579(01)01420-4]
95. Lentini, N.A.; Schroeder, C.M.; Harmon, N.M.; Huang, X.; Schladetsch, M.A.; Foust, B.J.; Poe, M.M.; Hsiao, C.-H.C.; Wiemer, A.J.; Wiemer, D.F. Synthesis and metabolism of BTN3A1 ligands: Studies on modifications of the allylic alcohol. ACS Med. Chem. Lett.; 2021; 12, pp. 136-142. [DOI: https://dx.doi.org/10.1021/acsmedchemlett.0c00586]
96. Gober, H.-J.; Kistowska, M.; Angman, L.; Jenö, P.; Mori, L.; De Libero, G. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med.; 2003; 197, pp. 163-168. [DOI: https://dx.doi.org/10.1084/jem.20021500]
97. Kunzmann, V.; Bauer, E.; Feurle, J.; Tony, F.W.H.P.; Wilhelm, M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood; 2000; 96, pp. 384-392. [DOI: https://dx.doi.org/10.1182/blood.V96.2.384]
98. Wiemer, A.J. Structure-activity relationships of butyrophilin 3 ligands. ChemMedChem; 2020; 15, pp. 1030-1039. [DOI: https://dx.doi.org/10.1002/cmdc.202000198]
99. Behr, C.; Poupot, R.; Peyrat, M.-A.; Poquet, Y.; Constant, P.; Dubois, P.; Bonneville, M.; Fournie, J.-J. Plasmodium falciparum stimuli for human γδ T cells are related to phosphorylated antigens of mycobacteria. Infect. Immun.; 1996; 64, pp. 2892-2896. [DOI: https://dx.doi.org/10.1128/iai.64.8.2892-2896.1996]
100. Hintz, M.; Reichenberg, A.; Altincicek, B.; Bahr, U.; Gschwind, R.M.; Kollas, A.-K.; Beck, E.; Wiesner, J.; Eberl, M.; Jomaa, H. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human γδ T cells in Escherichia coli. FEBS Lett.; 2001; 509, pp. 317-322. [DOI: https://dx.doi.org/10.1016/S0014-5793(01)03191-X]
101. Eberl, M.; Altincicek, B.; Kollas, A.-K.; Sanderbrand, S.; Bahr, U.; Reichenberg, A.; Beck, E.; Foster, D.; Wiesner, J.; Hintz, M. et al. Accumulation of a potent γδ T-cell stimulator after deletion of the lytB gene in Escherichia coli. Immunology; 2002; 106, pp. 200-211. [DOI: https://dx.doi.org/10.1046/j.1365-2567.2002.01414.x]
102. Eberl, M.; Hintz, M.; Reichenberg, A.; Kollas, A.-K.; Wiesner, J.; Jomaa, H. Microbial isoprenoid biosynthesis and human γδ T cell activation. FEBS Lett.; 2003; 544, pp. 4-10. [DOI: https://dx.doi.org/10.1016/S0014-5793(03)00483-6]
103. Espinosa, E.; Belmant, C.; Pont, F.; Luciani, B.; Poupot, R.; Romagné, F.; Brailly, H.; Bonneville, M.; Fournié, J.-J. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human γδ T cells. J. Biol. Chem.; 2001; 276, pp. 18337-18344. [DOI: https://dx.doi.org/10.1074/jbc.M100495200] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11279081]
104. Belmant, C.; Espinosa, E.; Halary, F.; Tang, Y.; Peyrat, M.-A.; Sicard, H.; Kozikowski, A.; Buelow, R.; Poupot, R.; Bonneville, M. et al. A chemical basis for recognition of nonpeptide antigens by human γδ T cells. FASEB J.; 2000; 14, pp. 1669-1670. [DOI: https://dx.doi.org/10.1096/fj.99-0909fje] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10973912]
105. Bennouna, J.; Levy, V.; Sicard, H.; Senellart, H.; Audrain, M.; Hiret, S.; Rolland, F.; Bruzzoni-Giovanelli, H.; Rimbert, M.; Galéa, C. et al. Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors. Cancer Immunol. Immunother.; 2010; 59, pp. 1521-1530. [DOI: https://dx.doi.org/10.1007/s00262-010-0879-0] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20563721]
106. Fournié, J.-J.; Sicard, H.; Poupot, M.; Bezombes, C.; Blanc, A.; Romagné, F.; Ysebaert, L.; Laurent, G. What lessons can be learned from γδ T cell-based cancer immunotherapy trials?. Cell. Mol. Immunol.; 2013; 10, pp. 35-41. [DOI: https://dx.doi.org/10.1038/cmi.2012.39]
107. Wiemer, D.F.; Wiemer, A.J. Opportunities and challenges in development of phosphoantigens as Vγ9Vδ2 T cell agonists. Biochem. Pharmacol.; 2014; 89, pp. 301-312. [DOI: https://dx.doi.org/10.1016/j.bcp.2014.03.009]
108. Sicard, H.; Ingoure, S.; Luciani, B.; Serraz, C.; Fournié, J.-J.; Bonneville, M.; Tiollier, J.; Romagné, F. In vivo immunomanipulation of Vγ9Vδ2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J. Immunol.; 2005; 175, pp. 5471-5480. [DOI: https://dx.doi.org/10.4049/jimmunol.175.8.5471]
109. Boëdec, A.; Sicard, H.; Dessolin, J.; Herbette, G.; Ingoure, S.; Raymond, C.; Belmant, C.; Kraus, J.-L. Synthesis and biological activity of phosphonate analogues and geometric isomers of the highly potent phosphoantigen (E)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate. J. Med. Chem.; 2008; 51, pp. 1747-1754. [DOI: https://dx.doi.org/10.1021/jm701101g]
110. Hsiao, C.-H.C.; Lin, X.; Barney, R.J.; Shippy, R.R.; Li, J.; Vinogradova, O.; Wiemer, D.F.; Wiemer, A.J. Synthesis of a phosphoantigen prodrug that potently activates Vγ9Vδ2 T-lymphocytes. Chem. Biol.; 2014; 21, pp. 945-954. [DOI: https://dx.doi.org/10.1016/j.chembiol.2014.06.006]
111. Shippy, R.R.; Lin, X.; Agabiti, S.S.; Li, J.; Zangari, B.M.; Foust, B.J.; Poe, M.M.; Hsiao, C.-H.C.; Vinogradova, O.; Wiemer, D.F. et al. Phosphinophosphonates and their tris-pivaloyloxymethyl prodrugs reveal a negatively cooperative butyrophilin activation mechanism. J. Med. Chem.; 2017; 60, pp. 2373-2382. [DOI: https://dx.doi.org/10.1021/acs.jmedchem.6b00965]
112. Foust, B.J.; Poe, M.M.; Lentini, N.A.; Hsiao, C.-H.C.; Wiemer, A.J.; Wiemer, D.F. Mixed aryl phosphonate prodrugs of a butyrophilin ligand. ACS Med. Chem. Lett.; 2017; 8, pp. 914-918. [DOI: https://dx.doi.org/10.1021/acsmedchemlett.7b00245]
113. Foust, B.J.; Li, J.; Hsiao, C.C.; Wiemer, D.F.; Wiemer, A.J. Stability and efficiency of mixed aryl phosphonate prodrugs. ChemMedChem; 2019; 14, pp. 1597-1603. [DOI: https://dx.doi.org/10.1002/cmdc.201900344]
114. Davey, M.S.; Malde, R.; Mykura, R.C.; Baker, A.T.; Taher, T.E.; Le Duff, C.S.; Willcox, B.E.; Mehellou, Y. Synthesis and biological evaluation of (E)-4-hydroxy-3-methylbut-2-enyl phosphate (HMBP) aryloxy triester phosphoramidate prodrugs as activators of Vγ9/Vδ2 T-cell immune responses. J. Med. Chem.; 2018; 61, pp. 2111-2117. [DOI: https://dx.doi.org/10.1021/acs.jmedchem.7b01824]
115. Lentini, N.A.; Foust, B.J.; Hsiao, C.-H.C.; Wiemer, A.J.; Wiemer, D.F. Phosphonamidate prodrugs of a butyrophilin ligand display plasma stability and potent Vγ9 Vδ2 T cell stimulation. J. Med. Chem.; 2018; 61, pp. 8658-8669. [DOI: https://dx.doi.org/10.1021/acs.jmedchem.8b00655]
116. Kadri, H.; Taher, T.E.; Xu, Q.; Sharif, M.; Ashby, E.; Bryan, R.T.; Willcox, B.E.; Mehellou, Y. Aryloxy diester phosphonamidate prodrugs of phosphoantigens (ProPAgens) as potent activators of Vγ9/Vδ2 T-cell immune responses. J. Med. Chem.; 2020; 63, pp. 11258-11270. [DOI: https://dx.doi.org/10.1021/acs.jmedchem.0c01232]
117. Harmon, N.M.; Huang, X.; Schladetsch, M.A.; Hsiao, C.-H.C.; Wiemer, A.J.; Wiemer, D.F. Potent double prodrug forms of synthetic phosphoantigens. Bioorg. Med. Chem.; 2020; 28, 115666. [DOI: https://dx.doi.org/10.1016/j.bmc.2020.115666]
118. Harmon, N.M.; Poe, M.M.; Huang, X.; Singh, R.; Foust, B.J.; Hsiao, C.-H.C.; Wiemer, D.F.; Wiemer, A.J. Synthesis and metabolism of BTN3A1 ligands: Studies on diene modifications to the phosphoantigen scaffold. ACS Med. Chem. Lett.; 2022; 13, pp. 164-170. [DOI: https://dx.doi.org/10.1021/acsmedchemlett.1c00408]
119. Shapiro, J.; Dworkin, M. Bacteria as Multicellular Organisms; Oxford University Press: Oxford, UK, 1997; ISBN 978-0-19-509159-5
120. Mowat, E.; Rajendran, R.; Williams, C.; McCulloch, E.; Jones, B.; Lang, S.; Ramage, G. Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation. FEMS Microbiol. Lett.; 2010; 313, pp. 96-102. [DOI: https://dx.doi.org/10.1111/j.1574-6968.2010.02130.x]
121. Schmidt, R.; Cordovez, V.; de Boer, W.; Raaijmakers, J.; Garbeva, P. Volatile affairs in microbial interactions. ISME J.; 2015; 9, pp. 2329-2335. [DOI: https://dx.doi.org/10.1038/ismej.2015.42]
122. Briard, B.; Heddergott, C.; Latgé, J.-P. Volatile compounds emitted by Pseudomonas aeruginosa stimulate growth of the fungal pathogen Aspergillus fumigatus. mBio; 2016; 7, e00219-16. [DOI: https://dx.doi.org/10.1128/mBio.00219-16]
123. Prescott, R.D.; Decho, A.W. Flexibility and adaptability of quorum sensing in nature. Trends Microbiol.; 2020; 28, pp. 436-444. [DOI: https://dx.doi.org/10.1016/j.tim.2019.12.004]
124. Duerre, J.A.; Baker, D.J. Structure elucidation of a carbohydrate derived from S-ribosylhomocysteine by enzymatic cleavage. Fed. Proc.; 1971; 30, 1067.
125. Bassler, B.L.; Wright, M.; Silverman, M.R. Multiple signalling systems controlling expression of luminescence in Vibrio harveyi: Sequence and function of genes encoding a second sensory pathway. Mol. Microbiol.; 1994; 13, pp. 273-286. [DOI: https://dx.doi.org/10.1111/j.1365-2958.1994.tb00422.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7984107]
126. Xavier, K.B.; Bassler, B.L. LuxS quorum sensing: More than just a numbers game. Curr. Opin. Microbiol.; 2003; 6, pp. 191-197. [DOI: https://dx.doi.org/10.1016/S1369-5274(03)00028-6] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12732311]
127. Di Cagno, R.; De Angelis, M.; Calasso, M.; Gobbetti, M. Proteomics of the bacterial cross-talk by quorum sensing. J. Proteomics; 2011; 74, pp. 19-34. [DOI: https://dx.doi.org/10.1016/j.jprot.2010.09.003] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20940064]
128. Lowery, C.A.; Park, J.; Kaufmann, G.F.; Janda, K.D. An unexpected switch in the modulation of AI-2-based quorum sensing discovered through synthetic 4,5-dihydroxy-2,3-pentanedione analogues. J. Am. Chem. Soc.; 2008; 130, pp. 9200-9201. [DOI: https://dx.doi.org/10.1021/ja802353j]
129. Duan, K.; Dammel, C.; Stein, J.; Rabin, H.; Surette, M.G. Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication: Modulation of P. aeruginosa by oropharyngeal flora. Mol. Microbiol.; 2003; 50, pp. 1477-1491. [DOI: https://dx.doi.org/10.1046/j.1365-2958.2003.03803.x]
130. Li, H.; Li, X.; Wang, Z.; Fu, Y.; Ai, Q.; Dong, Y.; Yu, J. Autoinducer-2 regulates Pseudomonas aeruginosa PAO1 biofilm formation and virulence production in a dose-dependent manner. BMC Microbiol.; 2015; 15, 192. [DOI: https://dx.doi.org/10.1186/s12866-015-0529-y]
131. Roy, V.; Meyer, M.T.; Smith, J.A.I.; Gamby, S.; Sintim, H.O.; Ghodssi, R.; Bentley, W.E. AI-2 analogs and antibiotics: A synergistic approach to reduce bacterial biofilms. Appl. Microbiol. Biotechnol.; 2013; 97, pp. 2627-2638. [DOI: https://dx.doi.org/10.1007/s00253-012-4404-6]
132. Kim, Y.; Oh, S.; Ahn, E.Y.; Imm, J.-Y.; Oh, S.; Park, S.; Kim, S.H. Proteome analysis of virulence factor regulated by autoinducer-2–like activity in Escherichia coli O157:H7. J. Food Prot.; 2007; 70, pp. 300-307. [DOI: https://dx.doi.org/10.4315/0362-028X-70.2.300]
133. Rohmer, M. The mevalonate-independent methylerythritol 4-phosphate (MEP) pathway for isoprenoid biosynthesis, including carotenoids. Pure Appl. Chem.; 1999; 71, pp. 2279-2284. [DOI: https://dx.doi.org/10.1351/pac199971122279]
134. Bernart, M.W.; Gerwick, W.H.; Corcoran, E.E.; Lee, A.Y.; Clardy, J. Laurencione, a heterocycle from the red alga Laurencia spectabilis. Phytochemistry; 1992; 31, pp. 1273-1276. [DOI: https://dx.doi.org/10.1016/0031-9422(92)80276-K]
135. Lowery, C.A.; McKenzie, K.M.; Qi, L.; Meijler, M.M.; Janda, K.D. Quorum sensing in Vibrio harveyi: Probing the specificity of the LuxP binding site. Bioorg. Med. Chem. Lett.; 2005; 15, pp. 2395-2398. [DOI: https://dx.doi.org/10.1016/j.bmcl.2005.02.069]
136. Gerwick, L.; Boudreau, P.; Choi, H.; Mascuch, S.; Villa, F.A.; Balunas, M.J.; Malloy, K.L.; Teasdale, M.E.; Rowley, D.C.; Gerwick, W.H. Interkingdom signaling by structurally related cyanobacterial and algal secondary metabolites. Phytochem. Rev.; 2013; 12, pp. 459-465. [DOI: https://dx.doi.org/10.1007/s11101-012-9237-5]
137. Geller, L.T.; Barzily-Rokni, M.; Danino, T.; Jonas, O.H.; Shental, N.; Nejman, D.; Gavert, N.; Zwang, Y.; Cooper, Z.A.; Shee, K. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science; 2017; 357, pp. 1156-1160. [DOI: https://dx.doi.org/10.1126/science.aah5043]
138. Geller, L.T.; Straussman, R. Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents. Mol. Cell. Oncol.; 2018; 5, e1405139. [DOI: https://dx.doi.org/10.1080/23723556.2017.1405139]
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Piechowiak, Teresa 2 ; Lièvremont, Didier 1 ; Rohmer, Michel 1
; Grosdemange-Billiard, Catherine 1 1 Laboratoire de Chimie et Biochimie de Molécules Bioactives—Université de Strasbourg/CNRS, UMR 7177, Institut Le Bel, 4 Rue Blaise Pascal, 67081 Strasbourg, France
2 Laboratoire de Chimie et Biochimie de Molécules Bioactives—Université de Strasbourg/CNRS, UMR 7177, Institut Le Bel, 4 Rue Blaise Pascal, 67081 Strasbourg, France; Unité de Chimie des Biomolécules, Institut Pasteur, Université Paris Cité, CNRS UMR3523, 75724 Paris, France